Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II

Summary

Matriptase is a type-II transmembrane serine protease involved in epithelial homeostasis in both health and disease, and is implicated in the development and progression of a variety of cancers. Matriptase mediates its biological effects both via as yet undefined substrates and pathways, and also by proteolytic cleavage of a variety of well-defined protein substrates, several of which it shares with the closely-related protease hepsin. Development of targeted therapeutic strategies will require discrimination between these proteases. Here we have investigated cyclic microproteins of the squash Momordica cochinchinensis trypsin-inhibitor family (generated by total chemical synthesis) and found MCoTI-II to be a high-affinity (K_i 9 nM) and highly selective (> 1,000-fold) inhibitor of matriptase. MCoTI-II efficiently inhibited the proteolytic activation of pro-hepatocyte growth factor (HGF) by matriptase but not by hepsin, in both purified and cell-based systems, and inhibited HGF-dependent cell scattering. MCoTI-II also selectively inhibited the invasion of matriptase-expressing prostate cancer cells. Using a model of epithelial cell tight junction assembly, we also found that MCoTI-II could effectively inhibit the re-establishment of tight junctions and epithelial barrier function in MDCK-I cells after disruption, consistent with the role of matriptase in regulating epithelial integrity. Surprisingly, MCoTI-II was unable to inhibit matriptase-dependent proteolytic activation of prostasin, a GPI-anchored serine protease also implicated in epithelial homeostasis. These observations suggest that the unusually high selectivity afforded by MCoTI-II and its biological effectiveness might represent a useful starting point for the development of therapeutic inhibitors, and further highlight the role of matriptase in epithelial maintenance.

Keywords

Serine protease - protease inhibitor - hepatocyte growth factor - epithelial cell - tight junctions - matriptase - cyclotide

• References

• 1 Ellis V, Murphy G. Cellular strategies for proteolytic targeting during migration and invasion. FEBS Lett 2001; 506: 1-5.
• 2 Qiu D, Owen K, Gray K. et al. Roles and regulation of membrane-associated serine proteases. Biochem Soc Trans 2007; 35: 583-587.
• 3 Szabo R, Wu Q, Dickson RB. et al. Type II transmembrane serine proteases. Thromb Haemost 2003; 90: 185-193.
• 4 Kang JY, Dolled-Filhart M, Ocal IT. et al. Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer. Cancer Res 2003; 63: 1101-1105.
• 5 Riddick AC, Shukla CJ, Pennington CJ. et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005; 92: 2171-2180.
• 6 List K, Szabo R, Molinolo A. et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes rasmediated malignant transformation. Genes Dev 2005; 19: 1934-1950.
• 7 Szabo R, Rasmussen AL, Moyer AB. et al. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 2011; 30: 2003-2016.
• 8 List K, Haudenschild CC, Szabo R. et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002; 21: 3765-3779.
• 9 Basel-Vanagaite L, Attia R, Ishida-Yamamoto A. et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet 2007; 80: 467-477.
• 10 List K, Kosa P, Szabo R. et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009; 175: 1453-1463.
• 11 Buzza MS, Netzel-Arnett S, Shea-Donohue T. et al. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 2010; 107: 4200-4205.
• 12 Takeuchi T, Harris JL, Huang W. et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-26342.
• 13 Owen KA, Qiu D, Alves J. et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 2010; 426: 219-228.
• 14 Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and Urokinase/Plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-36725.
• 15 Kilpatrick LM, Harris RL, Owen KA. et al. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616-2623.
• 16 Netzel-Arnett S, Currie BM, Szabo R. et al. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 2006; 281: 32941-32945.
• 17 Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009; 284: 23177-23181.
• 18 Kirchhofer D, Peek M, Lipari MT. et al. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005; 579: 1945-1950.
• 19 Moran P, Li W, Fan B. et al. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006; 281: 30439-30446.
• 20 Chen MQ, Chen LM, Lin CY. et al. Hepsin activates prostasin and cleaves the extracellular domain of the epidermal growth factor receptor. Mol Cell Biochem 2010; 337: 259-266.
• 21 Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 01: 727-730.
• 22 Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 02: 657-672.
• 23 Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
• 24 Werle M, Kafedjiiski K, Kolmar H. et al. Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration. Intern J Pharmaceut 2007; 332: 72-79.
• 25 Thongyoo P, Tate EW, Leatherbarrow RJ. Total synthesis of the macrocyclic cysteine knot microprotein MCoTI-II. Chem Commun 2006; 2848-2850.
• 26 Thongyoo P, Jaulent AM, Tate EW. et al. Immobilized protease-assisted synthesis of engineered cysteine-knot microproteins. Chembiochem 2007; 08: 1107-1109.
• 27 Thongyoo P, Bonomelli C, Leatherbarrow RJ. et al. Potent inhibitors of betatryptase and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem 2009; 52: 6197-6200.
• 28 Dukes JD, Whitley P, Chalmers AD. The MDCK variety pack: choosing the right strain. BMC Cell Biology 2011; 12: 43.
• 29 Förbs D, Thiel S, Stella MC. et al. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005; 27: 1061-1070.
• 30 Nigam SK, Rodriguez-Boulan E, Silver RB. Changes in intracellular calcium during the development of epithelial polarity and junctions. PNAS 1992; 89: 6162-6166.
• 31 Deu E, Verdoes M, Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol 2012; 19: 9-16.
• 32 Bode W, Turk D, Karshikov A. The refined 1.9-Å X-ray crystal structure of d-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 01: 426-471.
• 33 Friedrich R, Fuentes-Prior P, Ong E. et al. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem 2002; 277: 2160-2168.
• 34 Quimbar P, Malik U, Sommerhoff CP. et al. High-affinity cyclic peptide matriptase inhibitors. J Biol Chem 2013; 288: 13885-13896.
• 35 Stoop AA, Craik CS. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat Biotechnol 2003; 21: 1063-1068.
• 36 Desilets A, Longpre JM, Beaulieu ME. et al. Inhibition of human matriptase by eglin c variants. FEBS Lett 2006; 580: 2227-2232.
• 37 Li P, Jiang S, Lee SL. et al. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. J Med Chem 2007; 50: 5976-5983.
• 38 Fittler H, Avrutina O, Glotzbach B. et al. Combinatorial tuning of peptidic drug candidates: high-affinity matriptase inhibitors through incremental structure-guided optimization. Orga Biomol Chem 2013; 11: 1848-1857.
• 39 Salameh MA, Soares AS, Navaneetham D. et al. Determinants of Affinity and Proteolytic Stability in Interactions of Kunitz Family Protease Inhibitors with Mesotrypsin. J Biol Chem 2010; 285: 36884-36896.
• 40 Galkin AV, Mullen L, Fox WD. et al. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004; 61: 228-235.
• 41 Steinmetzer T, Schweinitz A, Sturzebecher A. et al. Secondary amides of sul-fonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 2006; 49: 4116-4126.
• 42 Xu ZH, Chen YW, Battu A. et al. Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade. J Med Chem 2011; 54: 7567-7578.
• 43 Szabo R, Hobson JP, Christoph K. et al. Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 2009; 136: 2653-2663.
• 44 Delaria KA, Muller DK, Marlor CW. et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12209-12214.
• 45 Scudamore CL, Jepson MA, Hirst BH. et al. The rat mucosal mast cell chymase, RMCP-II, alters epithelial cell monolayer permeability in association with altered distribution of the tight junction proteins ZO-1 and occludin. Eur J Cell Biol 1998; 75: 321-330.
• 46 Willemsen LEM, Hoetjes JP, Van Deventer SJH. et al. Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition. Clin Exp Immunol 2005; 142: 275-284.
• 47 Buzza MS, Martin EW, Driesbaugh KH. et al. Prostasin Is Required for Matriptase Activation in Intestinal Epithelial Cells to Regulate Closure of the Paracellular Pathway. J Biol Chem 2013; 288: 10328-10337.
• 48 Tripathi M, Potdar AA, Yamashita H. et al. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells. Prostate 2011; 71: 184-196.
• 49 Chen YW, Wang JK, Chou FP. et al. Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem 2010; 285: 31755-31762.
• 50 Tseng IC, Xu H, Chou FP. et al. Matriptase activation, an early cellular response to acidosis. J Biol Chem 2010; 285: 3261-3270.
• 51 Friis S, Uzzun Sales K, Godiksen S. et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: Prostasin as a non-enzymatic co-factor for matriptase activation. J Biol Chem 2013; 288: 19028-19039.
• 52 Kosa P, Szabo R, Molinolo AA. et al. Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Oncogene 2012; 31: 3679-3695.